ArticleProteomics2008
Profiling humoral immune responses to P. falciparum infection with protein microarrays.
Article in Proteomics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
159 citing papers in PubMed, 1 synthesis or guideline pooled it, 255 citations in OpenAlex.
- Meta-Analysis of Human Antibodies AgainstFrontiers in immunology · 2022Pooled it
- Trial
- Mother-Newborn Pairs in Malawi Have Similar Antibody Repertoires to Diverse Malaria Antigens.Clinical and vaccine immunology : CVI · 2017Trial
- A Library of Plasmodium vivax Recombinant Merozoite Proteins Reveals New Vaccine Candidates and Protein-Protein Interactions.PLoS neglected tropical diseases · 2015Trial
- RTS,S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver- and blood-stage parasites.Molecular & cellular proteomics : MCP · 2015Trial
- Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development.PloS one · 2015Trial
- Memory B-cell and antibody responses induced by Plasmodium falciparum sporozoite immunization.The Journal of infectious diseases · 2014Trial
- Proteome-wide characterization of Plasmodium vivax antigens using a high-density peptide array.PLoS pathogens · 2026Article
- The transmission-blocking dynamics of Plasmodium falciparum sexual-stage antibody responses in a six-year cohort of Ugandan children and adults.Nature communications · 2026Article
- Vaccine-induced mouse antibodies targeting Plasmodium falciparum PfVFT antigen inhibit blood stages through multiple mechanisms.NPJ vaccines · 2026Article
- The kinetics and transmission-blocking dynamics ofResearch square · 2026Article
- Vaccine-Induced Antibodies to a C-Terminal Plasmodium falciparum Circumsporozoite Protein Epitope Associated With Protection Against Malaria Challenge.The Journal of infectious diseases · 2026Article
- Immunoproteomics: The Evolution from Classical Methods to Emerging Techniques.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Complete attenuation of Plasmodium falciparum sporozoites by atovaquone-proguanil.EMBO molecular medicine · 2025Article
- Correlative humoral and cellular immunity to genetically attenuated malaria parasites in humans.iScience · 2025Article
- Antibody responses in Burkinabe children againstFrontiers in immunology · 2025Article
- Controlled human malaria infection with NF54 and 7G8 strains elicit differential antibody responses to Plasmodium falciparum peptides.Frontiers in immunology · 2025Article
- PfSPZ Vaccine induces focused humoral immune response in HIV positive and negative Tanzanian adults.EBioMedicine · 2024Article
- Profiling the antibody response of humans protected by immunization with Plasmodium vivax radiation-attenuated sporozoites.Scientific reports · 2024Article
- Article
99 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 3 countries.
Funding
Abstract
A complete description of the serological response following exposure of humans to complex pathogens is lacking and approaches suitable for accomplishing this are limited. Here we report, using malaria as a model, a method which elucidates the profile of antibodies that develop after natural or experimental infection or after vaccination with attenuated organisms, and which identifies immunoreactive antigens of interest for vaccine development or other applications. Expression vectors encoding 250 Plasmodium falciparum (Pf) proteins were generated by PCR/recombination cloning; the proteins were individually expressed with >90% efficiency in Escherichia coli cell-free in vitro transcription and translation reactions, and printed directly without purification onto microarray slides. The protein microarrays were probed with human sera from one of four groups which differed in immune status: sterile immunity or no immunity against experimental challenge following vaccination with radiation-attenuated Pf sporozoites, partial immunity acquired by natural exposure, and no previous exposure to Pf. Overall, 72 highly reactive Pf antigens were identified. Proteomic features associated with immunoreactivity were identified. Importantly, antibody profiles were distinct for each donor group. Information obtained from such analyses will facilitate identifying antigens for vaccine development, dissecting the molecular basis of immunity, monitoring the outcome of whole-organism vaccine trials, and identifying immune correlates of protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.